Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "Professor"

386 News Found

Sandu Pharmaceuticals launches Sandu Kumarvin
News | August 04, 2022

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients


Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’
News | July 18, 2022

Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’

Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru


CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine
News | July 15, 2022

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine

Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.


U.S. FDA grants emergency use authorization for Novavax COVID-19 vaccine
Drug Approval | July 15, 2022

U.S. FDA grants emergency use authorization for Novavax COVID-19 vaccine

Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.


NADMED brings first CE-marked NAD+ analysis kit to the market
Medical Device | June 30, 2022

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites


Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
News | June 29, 2022

Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3

Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study


Apollo Education UK launches the Apollo International Clinical Fellowship Programme
News | June 29, 2022

Apollo Education UK launches the Apollo International Clinical Fellowship Programme

Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.


Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
Drug Approval | June 28, 2022

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients


AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
News | June 22, 2022

AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza

LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)